Evaluation of Low-dose Darunavir in a Switch Study
Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
This is a switch study to assess the non-inferiority (in terms of efficacy and safety) of
darunavir (boosted with ritonavir, DRV/r 400mg/100mg daily) when compared with lopinavir
(boosted with ritonavir, LPV/r total dose 800mg/200mg daily), in combination with a
nucleoside backbone, administered as a second line therapy in HIV positive individuals.